Amarin Corp. Plc’s fish oil-derived drug and potential blockbuster Vascepa received a largely positive review from FDA staffers.

Amgen Inc. said starting in 2020, the drugmaker’s official list price for the cholesterol medicine Repatha will be the lower price the company began offering during 2019 to patients on Medicare and those paying for the drug out-of-pocket.

Pliant Therapeutics and Novartis reached a strategic collaboration and license deal to develop and commercialize integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis (NASH).

A U.S. judge set aside a jury verdict that found Amgen Inc. patents on the company’s cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc. and Sanofi SA, which sell rival drug Praluent.

The Medicines Company’s inclisiran hit the primary and secondary endpoints in a Phase III trial to decrease LDL cholesterol through twice-a-year dosing.

Regeneron Pharmaceuticals announced positive results from the company’s pivotal Phase III clinical trial of evinacumab in homozygous familial hypercholesterolemia (HoFH).

People who do not consistently get the same amount of sleep or go to bed at the same time each night may be more likely to develop health problems like obesity, high blood pressure, high cholesterol and diabetes, a recent study suggests.

Amarin Corp. provided an update, noting that the company is increasing revenue guidance for 2019 and is planning to expand the sales force for Vascepa due to faster-than-expected growth.

In veteran drug salesman Paul Hudson, Sanofi’s 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.

Germany’s highest civil court rejected French drugmaker Sanofi’s bid to fend off a legal challenge by U.S. rival Amgen against Sanofi’s cholesterol drug Praluent.